• Japanese
  • Korean
  • Chinese
Cover Image

Ovarian Cancer Partnering 2009-2014

The Ovarian Cancer Partnering 2009-2014 report provides understanding and access to the ovarian cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in ovarian cancer partnering deals

Top ovarian cancer deals by value

Deals listed by company A-Z, industry sector, stage of development, technology type

Description

The Ovarian Cancer Partnering 2009-2014 provides understanding and access to the ovarian cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of ovarian cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors ovarian cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report contains over 75 links to online copies of actual ovarian cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of ovarian cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in ovarian cancer partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading ovarian cancer deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of ovarian cancer partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the

research, development and commercialization of ovarian cancer technologies and products.

Report scope

Ovarian Cancer Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to ovarian cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

  • Trends in ovarian cancer dealmaking in the biopharma industry since 2009
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 75 ovarian cancer contract documents
  • The leading ovarian cancer deals by value since 2009

In Ovarian Cancer Partnering 2009-2014, the available deals are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Ovarian Cancer Partnering 2009-2014 provides the reader with the following key benefits:

  • In-depth understanding of ovarian cancer deal trends since 2009
  • Access to summary headline, upfront, milestone and royalty data
  • Comprehensive access to over 75 actual ovarian cancer deals entered into by the world's biopharma companies since 2009
  • Insight into key deal terms included in contracts, where disclosed
  • Understand the key deal terms companies have agreed in deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in ovarian cancer partnering

  • 2.1. Introduction
  • 2.2. Ovarian cancer partnering over the years
  • 2.3. Bigpharma ovarian cancer dealmaking activity
  • 2.4. Ovarian cancer partnering by deal type
  • 2.5. Ovarian cancer partnering industry sector
  • 2.6. Ovarian cancer partnering by stage of development
  • 2.7. Ovarian cancer partnering by technology type
  • 2.8. Disclosed financial deal terms for ovarian cancer
    • 2.8.1 Ovarian cancer headline values
    • 2.8.2 Ovarian cancer upfront payments
    • 2.8.3 Ovarian cancer milestone payments
    • 2.8.4 Ovarian cancer royalty rates

Chapter 3 - Leading ovarian cancer deals

  • 3.1. Introduction
  • 3.2. Top ovarian cancer deals by value
  • 3.3. Top ovarian cancer deals involving bigpharma

Chapter 4 - Dealmaking directory

  • 4.1. Introduction
  • 4.2. Company A-Z
  • 4.3. By deal type
  • Asset purchase
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Contract service
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Termination
  • 4.4. By industry sector
  • Academic
  • Bigpharma
  • Biotech
  • Drug delivery
  • Medical device
  • Diagnostic
  • Generic pharma
  • Government
  • Non-profit
  • Pharmaceutical
  • Research tools
  • Services
  • Specialty pharma
  • 4.5. By stage of development
  • Discovery
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Registration
  • Marketed
  • 4.6. By technology type
  • Analysis
  • Animal models
  • Assays
  • Bioinformatics
  • Biological compounds
  • Biomarkers
  • Biomaterials
  • Cell culture
  • Cell therapy
  • Clinical testing
  • Diagnostic - companion
  • Devices
  • Diagnostics
  • Discovery tools
  • DNA probes
  • Drug delivery
  • Enabling technology
  • Epigenetics
  • Equipment
  • Facilities
  • Gene therapy
  • Genomics
  • Imaging
  • Industrial chemicals
  • In vitro models
  • Monoclonal antibodies
  • Nanotechnology
  • Oligonucleotide
  • Peptides
  • Personalised medicine
  • Processes
  • Proteomics
  • Radio/Chemo-therapy
  • Recombinant DNA
  • Research services
  • Research supplies
  • RNA therapeutics
  • Screening
  • Small molecules
  • Stem cells
  • Vaccines

Chapter 5 - Partnering resource center

  • 5.1. Online partnering
  • 5.2. Partnering events
  • 5.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports
  • Table of figures
  • Figure 1: Ovarian cancer partnering since 2009
  • Figure 2: Bigpharma - top 50 - ovarian cancer deals 2009 to 2011
  • Figure 3: Bigpharma ovarian cancer deal frequency - 2009 to 2011
  • Figure 4: Ovarian cancer partnering by deal type since 2009
  • Figure 5: Ovarian cancer partnering by industry sector since 2009
  • Figure 6: Ovarian cancer partnering by stage of development since 2009
  • Figure 7: Ovarian cancer partnering by technology type since 2009
  • Figure 8: Ovarian cancer deals with a headline value
  • Figure 9: Ovarian cancer deals with upfront payment values
  • Figure 10: Ovarian cancer deals with milestone payments
  • Figure 11: Ovarian cancer deals with royalty rates, %
  • Figure 12: Top ovarian cancer deals by value since 2009
  • Figure 13: Top ovarian cancer deals signed by bigpharma value since 2009
  • Figure 14: Online partnering resources
  • Figure 15: Forthcoming partnering events
  • Figure 16: Deal type definitions
Show More
Pricing